The main types of Parkinson’s disease are idiopathic (classic) Parkinson’s, young-onset Parkinson’s, genetic Parkinson’s, vascular parkinsonism, drug-induced parkinsonism, and a group of faster-progressing conditions called atypical parkinsonism — which includes multiple system atrophy, progressive supranuclear palsy, corticobasal degeneration, and dementia with Lewy bodies. All of these produce similar core symptoms — tremor, slowness, stiffness, and balance problems — but they have different causes, different outlooks, and often need different treatment.
Roughly 15% of Parkinson’s cases are monogenic, meaning a single gene mutation drives the disease, while the atypical forms generally don’t respond to the standard medication levodopa and progress on a very different timeline. Getting the type right shapes everything from prognosis to which treatments are worth trying.
Parkinsonism vs. Parkinson’s Disease: A Quick Distinction
“Parkinsonism” is an umbrella term for any condition causing the classic movement symptoms — bradykinesia (slowed movement), rest tremor, rigidity, and postural instability. Parkinson’s disease is the most common cause of parkinsonism.
The Parkinson’s Foundation splits parkinsonism into two major groups: primary parkinsonian disorders (which includes Parkinson’s disease itself and the atypical forms) and secondary parkinsonism (caused by something external, like medication, stroke, or brain injury).
9 Types of Parkinson’s Disease and Parkinsonism
1. Idiopathic Parkinson’s Disease
This is “classic” Parkinson’s — the type most people picture, and the one Michael J. Fox and Muhammad Ali were diagnosed with. It’s called idiopathic because, in most cases, there’s no single identifiable cause. It results from the progressive loss of dopamine-producing neurons in a brain region called the substantia nigra.
Idiopathic PD is also the only type that reliably and substantially responds to levodopa, the gold-standard Parkinson’s medication. According to a scoping review updating the diagnostic criteria for the disease, an excellent levodopa response and classic rest tremor remain among the most useful supportive signs that distinguish true Parkinson’s from its look-alikes. Globally, this is by far the most common form: the worldwide prevalence of Parkinson’s disease rose from roughly 3.15 million cases in 1990 to 11.77 million in 2021 and continues to climb as populations age.
2. Young-Onset Parkinson’s Disease
Young-onset Parkinson’s is diagnosed before age 50 (some definitions use 40) and behaves somewhat differently than the late-onset form. In a large U.K. population study tracking Parkinson’s genetics, researchers found that of over 2,200 participants, 424 had young-onset disease, and this group carried a disproportionately higher share of identifiable genetic mutations than those diagnosed later in life.
3. Genetic (Familial) Parkinson’s Disease
While most Parkinson’s is sporadic, a meaningful minority is driven directly by inherited gene mutations. The most studied genes include LRRK2, GBA1, SNCA, PRKN (parkin), and PINK1. Research estimates that autosomal dominant and recessive PD-linked genes are found in about 5–10% of all Parkinson’s patients overall, with that number climbing sharply in early-onset and familial cases — up to 18% in patients diagnosed at age 30 or younger.
GBA1 mutations are the single most common genetic risk factor and are linked to a distinct clinical picture: patients with GBA-associated PD tend to show an earlier age at onset, faster disease progression, and higher rates of non-motor symptoms, such as REM sleep behavior disorder, autonomic dysfunction, and cognitive decline, compared with non-genetic Parkinson’s.
LRRK2-related Parkinson’s, by contrast, is often described as clinically indistinguishable from sporadic Parkinson’s on an individual level, though it tends to run a somewhat milder course in cognitive and autonomic domains.
4. Tremor-Dominant Parkinson’s Disease
Even within idiopathic Parkinson’s, doctors often describe two broad motor subtypes based on which symptoms dominate. Tremor-dominant (TD) Parkinson’s is marked mainly by resting tremor, with comparatively milder issues in gait and balance. Research comparing motor subtypes has found that tremor-dominant patients display more severe tremor at rest and action-postural tremor, and generally carry a somewhat better long-term prognosis than the alternative subtype below.
5. Postural Instability and Gait Difficulty (PIGD) Parkinson’s Disease
The other major motor subtype, PIGD, is dominated by balance problems, freezing of gait, and difficulty walking, with less prominent tremor. This subtype tends to be more aggressive. Studies directly comparing the two patterns found that PIGD patients have greater occupational disability, more cognitive impairment, more apathy, and more depression than tremor-dominant patients, along with a faster overall decline.
Interestingly, this may reflect disease stage as much as a fixed subtype. Longitudinal research has tracked patients shifting from tremor-dominant to PIGD as their disease advances, with one Norwegian cohort study showing an essentially one-directional transition from tremor-dominant toward PIGD with increasing disease duration, a shift that also carried a markedly higher risk of eventual dementia.
6. Multiple System Atrophy (MSA)
MSA is the first of the major “atypical parkinsonism” or “Parkinson-plus” conditions — a group that mimics Parkinson’s motor symptoms but has a different underlying cause, faster progression, and poor levodopa response. MSA specifically combines parkinsonism with severe autonomic dysfunction, affecting involuntary functions like heart rate, digestion, blood pressure, and bladder control. It’s further split into two subtypes depending on which symptoms dominate: MSA-P (parkinsonian features) and MSA-C (cerebellar, affecting coordination and balance).
7. Progressive Supranuclear Palsy (PSP)
PSP is another atypical parkinsonism, distinguished primarily by problems with eye movement and early, severe balance issues. Patients often struggle to look up or down and experience pronounced stiffness in the neck and trunk. It’s rare — but its public profile has grown in recent years; former U.S. Representative Jennifer Wexton’s diagnosis helped drive passage of the National Plan to End Parkinson’s Act in 2024. On imaging, PSP typically shows a distinctive pattern of midbrain atrophy on structural MRI, with frontal lobe hypometabolism visible on FDG-PET.
8. Corticobasal Degeneration (CBD)
CBD, sometimes called corticobasal syndrome, is a rarer atypical parkinsonism marked by asymmetric rigidity — symptoms that are often much worse on one side of the body — along with apraxia (difficulty performing learned movements) and, in some cases, an “alien limb” phenomenon where a limb seems to move involuntarily.
A comprehensive review of atypical parkinsonian disorders notes that CBD, along with PSP and MSA, remains genuinely difficult to diagnose early, since it can overlap heavily with Parkinson’s disease in its initial presentation and evolve unpredictably over time. Newer tools — including tau-PET imaging and fluid biomarkers like neurofilament light chain — are being developed specifically to catch these distinctions earlier.
9. Dementia with Lewy Bodies (DLB)
DLB is closely related to Parkinson’s on a molecular level (both involve abnormal clumps of the protein alpha-synuclein) but presents with early, prominent cognitive decline, visual hallucinations, and fluctuating alertness alongside motor symptoms.
It gained public attention after actor Robin Williams’ death, when early news reports mistakenly described his diagnosis as Parkinson’s disease rather than DLB. On imaging, DLB typically shows a recognizable pattern: parieto-occipital hypometabolism involving the cuneus on FDG-PET, which helps clinicians distinguish it from both Parkinson’s and Alzheimer’s-related dementia.
Secondary Parkinsonism: When Something Else Causes the Symptoms
Doctors also recognize secondary parkinsonism — cases where Parkinson’s-like symptoms are triggered by an outside cause rather than a primary neurodegenerative process. Common causes include:
- Drug-induced parkinsonism, caused by medications that block dopamine receptors, most often antipsychotics or certain anti-nausea drugs. It can closely resemble Parkinson’s disease, though the tremor and postural instability are often less severe, and symptoms frequently improve once the medication is stopped.
- Vascular parkinsonism, caused by reduced blood flow to the brain, often following small strokes, and typically affecting the lower body and gait more than the arms or tremor.
- Normal pressure hydrocephalus, caused by excess fluid buildup in the brain, which can sometimes improve if the fluid is drained — a meaningful difference from the permanent neurodegeneration seen in true Parkinson’s.
- Less commonly, brain tumors, toxin exposure (certain pesticides, industrial solvents, and historically Agent Orange), and repeated head trauma.
How Doctors Are Starting to Redefine These Categories
The types above are still based mostly on clinical symptoms — what a neurologist observes in an exam. That’s beginning to change. In 2024, researchers proposed the Neuronal Alpha-Synuclein Disease Integrated Staging System (NSD-ISS), a framework that classifies Parkinson’s based on measurable biology rather than symptoms alone — specifically, the presence of abnormal alpha-synuclein protein and dopamine system changes detectable through spinal fluid tests and imaging, even before obvious motor symptoms appear.
When researchers applied this system to a cohort of people with more established Parkinson’s, they found that tremor-dominant and PIGD motor patterns occurred in similar proportions across the biological disease stages, suggesting that a person’s underlying biological stage and their visible motor subtype don’t always line up cleanly — one more sign that Parkinson’s classification is shifting from “what does this look like” toward “what is actually happening in the brain.”
Why the Distinction Matters for Patients
Getting the type right changes:
- Treatment response. Idiopathic Parkinson’s generally responds well to levodopa; atypical forms like MSA, PSP, and CBD often don’t, which shapes realistic treatment expectations from the start.
- Prognosis. Atypical parkinsonism tends to progress faster and carries a poorer overall outlook than idiopathic Parkinson’s, so an accurate diagnosis helps patients and families plan appropriately.
- Non-motor symptom management. Depression, anxiety, and cognitive changes vary meaningfully by type — PIGD-dominant and DLB patients, for instance, face a higher burden of cognitive and mood symptoms than tremor-dominant patients, which affects how care teams monitor and support mental health alongside movement symptoms.
- Family and genetic counseling. For genetic forms like LRRK2- or GBA1-related Parkinson’s, an accurate diagnosis opens the door to genetic counseling for at-risk relatives.
Getting an Accurate Diagnosis
Because these conditions can look nearly identical in their early stages, an accurate diagnosis usually takes time and specialist evaluation. Movement disorder neurologists look at symptom patterns, response to levodopa over time, and increasingly, biomarker tools such as skin biopsy tests for abnormal alpha-synuclein, DaTscan imaging, and, in specialized centers, spinal fluid or tau-PET testing.
If you or someone you love has been told “it might be Parkinson’s, but we need to watch it,” that uncertainty is common and not a sign of poor care — it reflects how genuinely difficult these conditions are to tell apart early on.